AZD1305 + Placebo
Phase 2Completed 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Left Ventricle Function
Conditions
Left Ventricle Function
Trial Timeline
Aug 1, 2008 → Jul 1, 2009
NCT ID
NCT00748982About AZD1305 + Placebo
AZD1305 + Placebo is a phase 2 stage product being developed by AstraZeneca for Left Ventricle Function. The current trial status is completed. This product is registered under clinical trial identifier NCT00748982. Target conditions include Left Ventricle Function.
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (6)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00935025 | Phase 1 | Terminated |
| NCT00915356 | Phase 2 | Completed |
| NCT00748982 | Phase 2 | Completed |
| NCT00738322 | Phase 1 | Completed |
| NCT00688831 | Phase 1 | Completed |
| NCT00689039 | Phase 1 | Completed |
Competing Products
11 competing products in Left Ventricle Function
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Valsartan + Amlodipine + Hydrochlorothiazide + Losartan | Novartis | Phase 3 | 77 |
| Finerenone (BAY94-8862): intervention A + Finerenone (BAY94-8862): intervention B | Bayer | Phase 1 | 30 |
| Finerenone (Kerendia, BAY94-8862) | Bayer | Phase 3 | 74 |
| BAY2701250 IV + Placebo IV + BAY2701250 SC + Placebo SC | Bayer | Phase 1 | 30 |
| Finerenone (Kerendia, BAY94-8862) + Placebo | Bayer | Phase 3 | 74 |
| Diflucortolone valerate (BAY866146) | Bayer | Pre-clinical | 20 |
| Inhaled Iloprost + Placebo | Bayer | Phase 2 | 49 |
| Levosimendan | Orion Corporation | Pre-clinical | 20 |
| MK0954, /Duration of Treatment : 5 Years + Comparator : atenolol /Duration of Treatment : 5 Years | Organon | Phase 3 | 72 |
| Allo-hMSCs + Placebo | Longeveron | Phase 1 | 25 |
| Lomecel-B medicinal signaling cells | Longeveron | Phase 2 | 44 |